EXACT Sciences (EXAS) Trading Up 0%

Shares of EXACT Sciences Co. (NASDAQ:EXAS) were up 0% during mid-day trading on Thursday . The company traded as high as $46.16 and last traded at $45.64. Approximately 3,836,134 shares traded hands during mid-day trading, an increase of 31% from the average daily volume of 2,935,958 shares. The stock had previously closed at $45.64.

A number of analysts have issued reports on EXAS shares. Benchmark set a $65.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a report on Wednesday, January 17th. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Tuesday, January 16th. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. Bank of America set a $67.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a report on Monday, January 8th. Finally, BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $52.84.

The company has a current ratio of 7.15, a quick ratio of 6.77 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $4,977.95, a price-to-earnings ratio of -46.10 and a beta of 0.87.



EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The company had revenue of $87.41 million during the quarter, compared to the consensus estimate of $87.42 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. The firm’s quarterly revenue was up 148.0% on a year-over-year basis. equities analysts predict that EXACT Sciences Co. will post -0.92 earnings per share for the current year.

In related news, insider Kevin T. Conroy sold 125,402 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $52.79, for a total transaction of $6,619,971.58. Following the completion of the transaction, the insider now directly owns 955,454 shares in the company, valued at approximately $50,438,416.66. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP D Scott Coward sold 4,420 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $42.34, for a total transaction of $187,142.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 458,443 shares of company stock valued at $22,211,962. 4.00% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB acquired a new position in EXACT Sciences during the 4th quarter worth approximately $606,000. Probabilities Fund Management LLC acquired a new position in EXACT Sciences during the 4th quarter worth approximately $210,000. Salem Investment Counselors Inc. increased its position in EXACT Sciences by 548.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 6,480 shares of the medical research company’s stock worth $340,000 after purchasing an additional 5,480 shares in the last quarter. Doheny Asset Management CA acquired a new position in EXACT Sciences during the 4th quarter worth approximately $2,345,000. Finally, MetLife Investment Advisors LLC acquired a new position in EXACT Sciences during the 4th quarter worth approximately $2,855,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) Trading Up 0%” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/13/exact-sciences-exas-trading-up-0.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply